Submitted:
08 October 2024
Posted:
09 October 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Patients and Methods
3. Results
4. Discussion
5. Conclusion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Kamerman, P. Underdiagnosis of hypertension and diabetes mellitus in South Africa. S Afr Med J. 2022, 112, 53–60. [Google Scholar] [CrossRef]
- Tuttolomondo, A.; Maida, C.; Pinto, A. Diabetic foot syndrome: Immune-inflammatory features as possible cardiovascular markers in diabetes. World J Orthop. 2015, 6, 62–76. [Google Scholar] [CrossRef] [PubMed]
- Carro, G.V.; Saurral, R.; Saguez, F.S.; Witman, E.L. ‘Diabetic foot infections: Bacterial isolates from the centers and hospitals of Latin American countries’. The International Journal of Lower Extremity Wounds 2020, 21, 562–573. [Google Scholar] [CrossRef] [PubMed]
- Rossboth, S.; Lechleitner, M.; Oberaigner, W. Risk factors for diabetic foot complications in type 2 diabetes-A Systematic review. Endocrinol Diabetes Metab. 2020, 4, e00175. [Google Scholar] [CrossRef]
- Yu, Mk.; Lyeles, C.R.; Bent-Shaw, L.A.; Young, B.A. Sex disparities in diabetes process of care measures and self-care in high risk patients. J Diabetes Res. 2013, 2013, 575814. [Google Scholar] [CrossRef] [PubMed]
- Zhang, P.; Lu, J.; Jing, Y.; Tang, S.; Zhu, D.; Bi, Y. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis. Ann Med. 2017, 49, 106–116. [Google Scholar] [CrossRef]
- Abbas, Z.; Gill, G.; Archibald, L. The epidemiology of diabetic limb sepsis: an African perspective. Diabet Med. 2002, 19, 895–899. [Google Scholar] [CrossRef]
- Hicks, C.; Selvarajah, S.; Mathioudakis, N.; Sherman, R.; Hines, K.; Black, J.; et al. Burden of Infected Diabetic Foot Ulcers on Hospital Admissions and Costs. Ann Vasc Surg. 2016, 33, 149–158. [Google Scholar] [CrossRef]
- Spichler, A.; Hurwitz, B.; Armstrong, D.; Lipsky, B. Microbiology of diabetic foot infections: from Louis Pasteur to ‘crime scene investigation’. BMC Med. 2015, 13, 2. [Google Scholar] [CrossRef]
- Richard, J.; Lavigne, J.; Sotto, A. Diabetes and foot infection: more than double trouble. Diabetes Metab Res Rev. 2012, 28, 46–53. [Google Scholar] [CrossRef]
- Lipsky, B.; Berendt, A.; Cornia, P.; Pile, J.; Peters, E.; Armstrong, D.; Deery, G.; Embil, J.M.; Joseph, W.S.; Karchmer, A.W.; Pinzur, M.S.; Senneville, E. 2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections. Clin Infect Dis. 2012, 54, e132–e173. [Google Scholar] [CrossRef] [PubMed]
- Law, T.; Chibabhai, V.; Nana, T. Analysis and comparison of cumulative antibiograms for the Charlotte Maxeke Johannesburg Academic Hospital adult intensive care and high-care units, 2013 and 2017. S Afri Med J. 2019, 110, 55–64. [Google Scholar] [CrossRef] [PubMed]
- Nicolau, D.; Stein, G. Therapeutic Options for Diabetic Foot Infections; a review with emphasis on tissue penetration characteristics. J Am Podiatr Med Assoc. 2010, 100, 52–63. [Google Scholar] [PubMed]
- Lipsky, B. Diabetic Foot Infections: Microbiology Made Modern? Array of hope. Diabetes Care. 2007, 30, 2171–72. [Google Scholar] [CrossRef]
- Bhardwaj, S.; Mehra, P.; Dhanjal, D.S.; Sharma, P.; Sharma, V.; Singh, R.; Nepovimova, E.; Chopra, C.; Kuca, K. Antibiotics and antibiotics resistance-Flip sides of the same coin. Curr Pharm Des. 2022, 28, 3212–2329. [Google Scholar] [CrossRef] [PubMed]
- Pang, Z.; Raudonis, R.; Glick, B.R.; Lin, T.J.; Cheng, Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanism and alternative therapeutic strategies. Biotechnol Adv. 2019, 37, 177–192. [Google Scholar] [CrossRef]
- Sultana, R.; Ahmed, I.; Saima, S.; Salam, M.T.; Sultana, S. Diabetic foot ulcer-a systematic review on relevant microbial etiology and antibiotic resistance in Asian countries. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2023, 17, 102783. [Google Scholar] [CrossRef]
- Gregg, E.W.; Sattar, N.; Ali, M.K. The changing face of diabetes complications. Lancet Diabetes Endocrinol. 2016, 4, 537–547. [Google Scholar] [CrossRef]
- Laakso, M.; Kiiski, J.; Karppelin, M.; Helminen, M.; Kaartinen, I. Pathogens causing diabetic foot infection and the reliability of the superficial culture. Surgical Infection 2021, 22, 334–339. [Google Scholar] [CrossRef]
- Nyamu, P.N.; Otieno, C.F.; Amayo, E.O.; McLigeyo, S.O. Risk factors and prevalence of diabetic foot ulcers at Kenyatta National Hospital, Nairobi. East Afr Med J. 2003, 80, 36–43. [Google Scholar] [CrossRef]
- Ghotaslou, R.; Memar, M.Y.; Alizadeh, N. Classification, microbiology and treatment of diabetic foot infections. Journal of Wound Care 2018, 27, 434–441. [Google Scholar] [CrossRef] [PubMed]
- McNeely, M.J.; Boyko, E.J.; Ahroni, J.H.; Stensel, V.L.; Reiber, G.E.; Smith, D.G.; Pecoraro, R.F. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration: How great are the risks? Diabetes Care. 1995, 18, 216–219. [Google Scholar] [CrossRef] [PubMed]
- Hicks, C.W.; Canner, J.K.; Mathioudakis, N.; Sherman, R.; Malas, M.B.; Black 3rd, J.H.; Abularrage, C.J. The Society for Vascular Surgery Wound, ischemia, and foot infection (WIFI) classification system correlates with cost of care for diabetic foot ulcers treated in a multidisciplinary setting. Journal of Vascular Surgery 2018, 67, 1455–1462. [Google Scholar] [CrossRef] [PubMed]
- Usman, Y.; Bakari, A.; Abdullahi, I.N.; Ahmad, A.; Sani-Bello, F.; Sagay, A.; Olayinka, A.T. Phenotypic profile and antibiogram of biofilm-producing bacteria isolates from diabetic foot ulcers in Zaria, Nigeria. Niger Postgrad Med J. 2021, 28, 233–239. [Google Scholar] [CrossRef] [PubMed]
- Sasikumar, K.; Vijayakumar, C.; Jagdish, S.; Kadambari, D.; Kumar, N.R.; Biswas, R.; Parija, S.C. Clinico-microbiological profile of septic diabetic foot with special reference to anaerobic infection. Cureus. 2018, 10, e2252. [Google Scholar] [CrossRef]
- Macdonald, K.E.; Boeckh, S.; Stacey, H.J.; Jones, J.D. The microbiology of diabetic foot infections: a meta-analysis. BMC Infect Dise. 2021, 21, 770. [Google Scholar] [CrossRef]
- Shobo, C.O.; Essack, S.Y.; Bester, L.A. Enterococcal contamination of hospital environment in Kwazulu-Natal South Africa. J Appl Microbiol. 2022, 132, 654–664. [Google Scholar] [CrossRef]
- Garcia-Solache, M.; Rice, L.B. The enterococcus: a Model of Adaptability to Its Environment. Clin Microbiol Rev. 2019, 32, e00058. [Google Scholar] [CrossRef]
- Osei Sekyere, J.; Mensah, E. Molecular epidemiology and mechanisms of antibiotic resistance inenterococcus spp., staphylococcus spp., and streptococcus spp. in Africa: A systematic review from a one health perspective. Annals of the New York Academy of Sciences 2019, 1465, 29–58. [Google Scholar] [CrossRef]
- Serra, R.; Grande, R.; Butrico, L.; Rossi, A.; Settimio, U.F.; Amato, B.; et al. Chronic wound infections: the role of pseudomonas aeruginosa and staphylococcus aureus. Expert Rev Anti Infect Ther. 2015, 13, 605–13. [Google Scholar] [CrossRef]
- Darling, J.D.; McCallum, J.C.; Soden, P.A.; Guzman, R.J.; Wyers, M.C.; Hamdan, A.D.; Verhagen, H.J.; Schermerhorn, M.L. Predictive ability of the Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification system after first-time lower extremity revascularization. J Vasc Surg. 2017, 65, 695–704. [Google Scholar] [CrossRef] [PubMed]
- Cull, D.L.; Manos, G.; Hartley, M.C.; et al. An early validation of the Society for Vascular Surgery Lower Extremity Threatened Limb Classification System. J Vasc Surg. 2014, 60, 1535–41. [Google Scholar] [CrossRef] [PubMed]
- Darling, J.D.; McCallum, J.C.; Soden, P.A.; et al. Predictive ability of the Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification system following infrapopliteal endovascular interventions for critical limb ischaemia. J Vasc Surg. 2016, 64, 616–22. [Google Scholar] [CrossRef] [PubMed]
- Snyder, R.J.; Bohn, G.; Hanft, J.; Harkless, L.; Kim, P.; Lavery, L.; Schultz, G.; Wolcott, R. Wound biofilm: Current perspectives and strategies on Biofilm disruption and treatment. Wounds. 2017, 29, S1–S17. [Google Scholar]
- Kollef, M.H.; Shorr, A.F.; Bassetti, M.; Timsit, J.-F.; Micek, S.T.; Michelson, A.P.; Garnacho-Montero, J. Timing of antibiotic therapy in the ICU. Critical Care 2021, 25. [Google Scholar] [CrossRef]


| Variable | Overall | Male | Female | p-value |
|---|---|---|---|---|
| Age years (median, IQR) | 59(54-67) | 58(54-65) | 61(54-67) | 0.139 |
| Racial group | ||||
| African | 89(53%) | 54(50%) | 35(58%) | |
| White | 44(26%) | 32(30%) | 12(20%) | |
| Indian | 30(18%) | 19(18%) | 11(19%) | |
| Coloured | 5((3%) | 3(2%) | 2(3%) | |
| Type of DM | ||||
| Type 1 DM | 9(4.4%) | 6 (5.6%) | 3(5%) | 0.98 |
| Type II DM | 159(94.6%) | 102(94.4%) | 57(95%) | |
| Nature of infection | ||||
| Wet gangrene/sepsis | 161(95.8%) | 101(93.5%) | 60(100%) | 0.398 |
| Ulcers/cellulitis | 2(1.2%) | 2(1.9%) | 0(0%) | |
| Not specified | 5(3%) | 5(4.6%) | 0(0%) | |
| Anatomical extent | ||||
| Toes | 59(35.7%) | 34(31.5%) | 26(43.3%) | 0.67 |
| Mid-foot | 94(56%) | 66(61.1%) | 28(46.8%) | |
| Ankle | 4(2.3%) | 3(2.8%) | 1(1.6%) | |
| Below the knee | 10(6%) | 5(4.6%) | 5(8.3%) | |
| Variable | Overall | Male | Female | p-value |
|---|---|---|---|---|
| White cell count (X109/L) | 10.91(8.32-15.45) | 10.99(8.5-14.95) | 10.61(8.2-15.69) | 0.438 |
| C-reactive protein (mg/L) | 133.5(5.6.5-247). | 153(57-268) | 94(57-184.5) | 0.091 |
| Urea (mmol/L) | 7.1(5.3-9.9) | 7.7(6.0-11.3) | 6.65(3.9-8.53) | 0.036 |
| Creatinine(umol/L) | 88(68-136) | 100(68-153.8) | 81(62-102) | 0.162 |
| Albumin(g/L) | 36(24-39) | 35(23-40) | 37(30.5-39) | 0.109 |
| Haemoglobin A1c (%) | 11.1 (8.23-12.6) | 9.8(8.1-12.2) | 11.4(8.85-13) | 0.266 |
| Specimen sampling (n=106) | ||||
| Tissue | 64 (60.4%) | 49 (73.1%) | 15(38.5%) | 0.018 |
| Pus swab (deep) | 15(14.2%) | 7(10.4%) | 8(20.5%) | |
| Aspiration | 7(6.6%) | 1(1.5%) | 6(15.4%) | |
| Blood cultures | 20(18.8%) | 10(14.9%) | 10(25.6%) | |
| Polymicrobial | 77% | 79% | 50% | |
| Documented antibiotic treatment | 76(45.2%) | 52 (48.1%) | 24(40%) | 0.69 |
| Organism | Percentage |
|---|---|
| Enterococcus faecalis | 16.9% |
| Staphylococcus aureus | 9.2% |
| Klebsiella pneumoniae | 7.7% |
| Proteus mirabilis | 7.7% |
| Morganella morganii | 6.2% |
| Escherichia coli | 6.2% |
| Serratia marcescens | 2.8% |
| Enterococcus faecalis | 14.3% |
| Proteus mirabilis | 14.3% |
| Pseudomonas aeruginosa | 14.3% |
| Streptococcus agalactiae | 8.6% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).